Cerenome reports interim Respect-LM data supporting repeat dosing of Reyobiq in leptomeningeal metastases at the 2026 SNO Annual Meeting
CNSY•Cerenome reported interim Respect-LM data supporting repeat dosing of Reyobiq in leptomeningeal metastases. No dose-limiting toxicities or adverse events leading to discontinuation were reported.
1. Interim study data
Cerenome reported interim Respect-LM data supporting repeat dosing of Reyobiq in leptomeningeal metastases at the 2026 SNO Annual Meeting. The company reported no dose-limiting toxicities or adverse events leading to discontinuation.



